The majority of Benign Prostate Hyperplasia (BPH) laser procedures are performed today using the vaporization method of tissue ablation, as it is a minimally invasive, clinically effective, intuitive procedure which is modelled after the gold standard of care (Trans Urethral Resection of the Prostate). Recently, a new procedure referred to as laser “enucleation” of the prostate has demonstrated the ability to remove excess prostatic tissue with a variety of different laser wavelengths. A more involved and complex procedure with a longer learning curve, enucleation comprises cutting out sections of the prostate using a laser and end cutting fibers and then removing those segments with a device called a morcellator.
A less common alternative for the treatment of BPH, Diode Laser Enucleation of the Prostate (DILEP) must be performed in an operating room environment and typically requires overnight stay as it is a more involved procedure than vaporization. Regardless, where the decision may be made that enucleation is the preferred treatment option for the case, the Pathfinder diode laser delivers all of the same benefits to the hospital including; portability (110V power), compact design, ease of use (including pre-set enucleation settings), and affordability of the laser device and consumable fibers. In comparison to performance benefits versus other lasers which enucleate, the Pathfinder boasts high ablation rates (tissue removal) with durable coagulation, which enhances visibility and reduces total treatment time for this procedure.
For more information on how the Pathfinder TURP laser can enhance the quality of patient care while reducing operational costs, contact the team at Surgical Lasers Inc. today.